AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04120948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterlase Express Laser System
Description: 10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
Study NCT04120948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tongue scraper
Description: mechanical scraping of the dorso-posterior surface of the tongue
Study NCT04148820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin, Atorvastatin, Perindopril
Description: Cardiovascular drugs will be administered all together every day at the same time
Study NCT02498613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT02498613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Correlative studies
Study NCT04389255 — intervention group
Intervention type: OTHER
Intervention: Star Excursion Balance Test
Description: The Star Excursion Balance Test (SEBT) is a dynamic test that requires strength, flexibility, and proprioception. It is a measure of dynamic balance that provides a significant challenge to athletes and physically active individuals. The test can be used to assess physical performance, but can also be used to screen deficits in dynamic postural control due to musculoskeletal injuries (e.g. chronic ankle instability), to identify athletes at greater risk for lower extremity injury, as well as during the rehabilitation of orthopeadic injuries in healthy active adults.\[
Study NCT04389255 — intervention group
Intervention type: DEVICE
Intervention: Balance Master device
Description: The Balance Master (Neurocom International, Inc Clackamas,) device is a computerized posturography device. The device consists of a fixed support surface consisting of a force table and individuals, a variety of ground elements and a computer screen that will provide visual feedback and conduct test protocols. Posturography tests a person's ability to integrate visual, vestibular and somatosensory inputs and suppress inappropriate sensory information. Thus, it can quantitatively score the person's balance and examine balance problems in detail with the tests it contains. There are various protocols that evaluate balance differently in Balance Master (BMc). Limits of Stability Test (LOS) and Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) were used in the BMc.
Study NCT04069546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: RIC is a physical strategy performed by an electric device with cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times.
Study NCT03381391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: The current intervention included personalized feedback regarding their alcohol consumption, alcohol-related consequences, gender-specific normative drinking comparisons, personal risk factors (e.g., dependence symptoms, family history of alcoholism), and alcohol expectancies. The intervention also included didactic material related to alcohol (e.g., effects at different BAC levels, tolerance) and drinking moderation strategies. The feedback was presented graphically in a feedback report with the individual's information.
Study NCT00555347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Dosage 150-250 mg
Study NCT00555347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00884611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictive Low Glucose Suspend Algorithm ON
Description: The algorithm uses a Kalman filter-based model to predict whether the sensor glucose level will fall below 80 mg/dL within a given time period and suspends the insulin pump if this event is predicted.
Study NCT00884611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictive Low Glucose Suspend Algorithm OFF
Study NCT04315220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corestability training
Description: Level -1: Mat exercises~Abdominal muscle contraction,bridging,cat stretch,single limb circle and superman.:~Level- 2: Swiss Ball Exercises Abdominal contraction,bridging and squats.
Study NCT02528058 — intervention group
Intervention type: PROCEDURE
Intervention: Vitrectomy with internal limiting membrane peeling
Study NCT02833831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176
Description: Participants will receive a single dose of ALS-008176 orally.
Study NCT02833831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be administered.
Study NCT02833831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single dose of moxifloxacin 400 mg.
Study NCT03298373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
Study NCT01897441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03298373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11β-methyl-nortestosterone-dodecylcarbonate
Description: 11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
Study NCT02193477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
Study NCT02193477 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TEAS
Description: Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
Study NCT03528096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnomat B
Description: Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
Study NCT01897441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01897441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01897441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT03528096 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sound
Description: Sound of the moving bed was recorded and played back during the baseline night.
Study NCT04030338 — intervention group
Intervention type: DRUG
Intervention: 18F-DCFPyL-iPSMA
Description: Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
Study NCT04030338 — intervention group
Intervention type: DRUG
Intervention: 68Ga-HBED-iPSMA
Description: Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
Study NCT04030338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT scan
Description: The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed
Study NCT01547507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirWay Medix Closed Suction System
Description: AirWay Medix Closed Suction System
Study NCT01897441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Patients with ER-positive, HER2-negative disease may receive neoadjuvant endocrine therapy (NET) with an aromatase inhibitor: (either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily) for 4-6 months prior to surgery (or longer if clinically indicated). Anastrozole for 6 months is the preferred regimen for NET.
Study NCT02959710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204 mixed in water
Description: 40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
Study NCT02927782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.
Study NCT02927782 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bed Rest
Description: 48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
Study NCT02955797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 milliliter (mL), Intramuscular
Study NCT02955797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine
Description: 0.5 mL, Intramuscular
Study NCT02955797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study NCT02770170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064 dose 1
Study NCT02770170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064 dose 2
Study NCT02770170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064 dose 3
Study NCT02770170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01443273 — intervention group
Intervention type: OTHER
Intervention: Medical Records study
Description: No interventions will be done related to the study besides summary of the Medical Files.
Study NCT02028312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate
Study NCT02028312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears
Study NCT02028312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Restasis
Study NCT02028312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Study NCT04357340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Physiotherapy Techniques
Description: Participants will receive pulmonary physiotherapy techniques in six session during three days (twice daily). Four distinguished interventions will be provided for the patients: 1) Chest expansion exercises (for prevention and treatment of potential atelectasis); 2) Techniques to Mobilize or loosen the pulmonary secretions (Active cycle breathing, Coughing techniques, Vibration and Postural drainage); 3) Hold breathing exercise (3 sets, 10 repetition) and; 4) Walking training (based on patient's tolerance until 6 minute).
Study NCT02660931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AKI Risk Notification
Description: When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
Study NCT05076396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM14
Description: PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety. Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
Study NCT03203070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizol iv
Description: Postoperative analgesia iv with Metamizol 2g/8h will be administered.
Study NCT03203070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol iv
Description: Postoperative analgesia iv with Metamizol 2g/8h will be administered.
Study NCT03203070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Intraoperative laparoscopic-guided TAP block will be performed with 30ml Bupivacaine 0.5%
Study NCT02759874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: specialized breathalyzer w face recognition technology
Study NCT03624244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Maintenance of AI versus interruption of AI
Study NCT03624244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aromatase Inhibitors
Description: Maintenance of AI versus interruption of AI
Study NCT01898208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilmArray testing
Description: FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
Study NCT02959710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202 mixed in water
Description: 60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
Study NCT02959710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202 mixed in Ensure®
Description: 60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)
Study NCT03756961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia
Study NCT03756961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia
Study NCT03756961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia
Study NCT03756961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia
Study NCT03756961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: The control group receives Oxycodone as the routine pain management drug post-operative.
Study NCT01898208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial Stewardship
Description: Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
Study NCT01898208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial culture
Description: This test identifies the pathogen responsible for an infection.
Study NCT01898208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Susceptibility testing
Description: Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
Study NCT04160962 — intervention group
Intervention type: PROCEDURE
Intervention: lappg
Description: Laparoscopic gastrectomy for pylorus preservation
Study NCT04896879 — intervention group
Intervention type: BEHAVIORAL
Intervention: interviews
Description: semi-structured interviews will be conducted in patients with major LARS and their informal caregiver to explore their experiences and needs. Focus groups will be perfomed with healthcare professionals of several professions.
Study NCT04315220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: No Intervention
Study NCT01750957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally daily, 12 weeks
Study NCT01750957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Dose A orally daily, 12 weeks
Study NCT01750957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Dose B orally daily, 12 weeks
Study NCT02718469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Vaccine - low dose
Description: 2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
Study NCT02718469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Vaccine - mid dose
Description: 2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
Study NCT02718469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Vaccine - high dose
Description: 2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
Study NCT02718469 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
Study NCT03142789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Initial bolus (Certa and standard catheter groups)
Description: 10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.
Study NCT03142789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Initial bolus (Single bolus group)
Description: 20 ml of ropivacaine 0.75%
Study NCT03142789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent boluses (Certa and standard catheter groups)
Description: 20 ml of ropivacaine 0.2% every 8 hour in the catheter
Study NCT03142789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent boluses (Single bolus group)
Description: 0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
Study NCT04863105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)
Description: Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study.
Study NCT01989442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: binasal prongs
Description: patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support
Study NCT01989442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal mask
Description: patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
Study NCT00854139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, anti-thymocyte globulin
Description: Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications
Study NCT00854139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Description: On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
Study NCT00854139 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thymic irradiation
Description: Thymic irradiation 7 Gy on Day -1
Study NCT00854139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant from a related donor
Description: • Donor bone marrow (> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is > 60 seconds, the protamine treatment shall be repeated